Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/21326
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorSARTORI, Ana Marli Christovam-
dc.contributor.authorROZMAN, Luciana Martins-
dc.contributor.authorDECIMONI, Tassia Cristina-
dc.contributor.authorLEANDRO, Roseli-
dc.contributor.authorNOVAES, Hillegonda Maria Dutilh-
dc.contributor.authorSOAREZ, Patricia Coelho de-
dc.date.accessioned2017-08-17T19:16:43Z-
dc.date.available2017-08-17T19:16:43Z-
dc.date.issued2017-
dc.identifier.citationHUMAN VACCINES & IMMUNOTHERAPEUTICS, v.13, n.6, p.1454-1465, 2017-
dc.identifier.issn2164-5515-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/21326-
dc.description.abstractBackground: In Brazil, since 2005, the Ministry of Health requires Health Economic Evaluation (HEE) of vaccines for introduction into the National Immunization Program.Objectives: To describe and analyze the full HEE on vaccines conducted in Brazil from 1980 to 2013.Methods: Systematic review of the literature. We searched multiple databases. Two researchers independently selected the studies and extracted the data. The methodological quality of individual studies was evaluated using CHEERS items.Results: Twenty studies were reviewed. The most evaluated vaccines were pneumococcal (25%) and HPV (15%). The most used types of HEE were cost-effectiveness analysis (45%) and cost-utility analysis (20%). The research question and compared strategies were stated in all 20 studies and the target population was clear in 95%. Nevertheless, many studies did not inform the perspective of analysis or data sources.Conclusions: HEE of vaccines in Brazil has increased since 2008. However, the studies still have methodological deficiencies.-
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Sao Paulo Research Foundation), as part of a larger project entitled ""Systematic review of health economic evaluations conducted in Brazil (FAPESP) [2012/22126-3]-
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, National Counsel of Technological and Scientific Development) - CNPq ) [305614/2013-4]-
dc.description.sponsorshipNational Institute of Science and Technology for Health Technology Assessment (IATS) - CNPq/Brazil-
dc.language.isoeng-
dc.publisherTAYLOR & FRANCIS INC-
dc.relation.ispartofHuman Vaccines & Immunotherapeutics-
dc.rightsrestrictedAccess-
dc.subjectBrazil-
dc.subjectcost-benefit analysis-
dc.subjectcost effectiveness-
dc.subjecteconomic evaluation-
dc.subjectimmunization programs-
dc.subjectsystematic review-
dc.subjectvaccines-
dc.subject.othercost-effectiveness analysis-
dc.subject.otherpneumococcal conjugate vaccine-
dc.subject.otherdecision-making-
dc.subject.othereffectiveness thresholds-
dc.subject.otherimmunization program-
dc.subject.otherhuman-papillomavirus-
dc.subject.othersao-paulo-
dc.subject.otherimpact-
dc.subject.othertuberculosis-
dc.subject.otherexperience-
dc.titleA systematic review of health economic evaluations of vaccines in Brazil-
dc.typearticle-
dc.rights.holderCopyright TAYLOR & FRANCIS INC-
dc.identifier.doi10.1080/21645515.2017.1282588-
dc.identifier.pmid28129026-
dc.subject.wosBiotechnology & Applied Microbiology-
dc.subject.wosImmunology-
dc.type.categoryreview-
dc.type.versionpublishedVersion-
hcfmusp.description.beginpage1454-
hcfmusp.description.endpage1465-
hcfmusp.description.issue6-
hcfmusp.description.volume13-
hcfmusp.origemWOS-
hcfmusp.origem.id2-s2.0-85020895384-
hcfmusp.origem.idWOS:000403958500032-
hcfmusp.publisher.cityPHILADELPHIA-
hcfmusp.publisher.countryUSA-
hcfmusp.relation.referenceAndrade MV, 2013, CAD SAUDE PUBLICA, V29, pS59, DOI 10.1590/0102-311X00021113-
hcfmusp.relation.referenceAndrade M. V., 2013, VALUE HLTH REGIONAL, V2, P405, DOI 10.1016/J.VHRI.2013.01.009-
hcfmusp.relation.referenceAnonychuk AM, 2008, PHARMACOECONOMICS, V26, P17-
hcfmusp.relation.referenceBarnighausen T, 2012, CLIN MICROBIOL INFEC, V18, P70, DOI 10.1111/j.1469-0691.2012.03977.x-
hcfmusp.relation.referenceBarnighausen T, 2014, P NATL ACAD SCI USA, V111, P12313, DOI 10.1073/pnas.1400475111-
hcfmusp.relation.referenceBarbieri M, 2010, VALUE HEALTH, V13, P1028, DOI 10.1111/j.1524-4733.2010.00771.x-
hcfmusp.relation.referenceBasu A, 2004, SCHIZOPHR RES, V71, P445, DOI 10.1016/j.schres.2004.02.012-
hcfmusp.relation.referenceBertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418-
hcfmusp.relation.referenceBeutels P, 2008, LANCET INFECT DIS, V8, P727, DOI 10.1016/S1473-3099(08)70258-5-
hcfmusp.relation.referenceBurckel E, 1999, PHARMACOECONOMICS, V16, P563, DOI 10.2165/00019053-199916050-00012-
hcfmusp.relation.referenceCampolina AG, 2011, CIENC SAUDE COLETIVA, V16, P3103, DOI 10.1590/S1413-81232011000800010-
hcfmusp.relation.referenceCatala-Lopez F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069462-
hcfmusp.relation.referenceCDC, 2005, MMWR-MORBID MORTAL W, V54, P893-
hcfmusp.relation.referenceChit A, 2016, HUM VACC IMMUNOTHER, V12, P1257, DOI 10.1080/21645515.2015.1137405-
hcfmusp.relation.referenceSartori AMC, 2016, VACCINE, V34, P1531, DOI 10.1016/j.vaccine.2016.02.026-
hcfmusp.relation.referenceSartori AMC, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049005492-
hcfmusp.relation.referenceSartori AMC, 2012, J EPIDEMIOL COMMUN H, V66, P210, DOI 10.1136/jech.2010.111880-
hcfmusp.relation.referenceCONITEC, 2013, COM NAC INC TECHN SU-
hcfmusp.relation.referenceConstenla DO, 2008, J HEALTH POPUL NUTR, V26, P388-
hcfmusp.relation.referenceCosta JG, 2005, REV SAUDE PUBL, V39, P122, DOI [10.1590/S0034-89102005000100016, 10.1590/s0034-89102005000100016]-
hcfmusp.relation.referenceSystematic reviews of economic evaluations, 2009, SYST REV EC EV CRD G-
hcfmusp.relation.referenceCruz LN, 2011, VALUE HEALTH, V14, pS108, DOI 10.1016/j.jval.2011.05.012-
hcfmusp.relation.referencede Soarez PC, 2008, REV PANAM SALUD PUBL, V23, P221-
hcfmusp.relation.referencede Soarez PC, 2011, VALUE HEALTH, V14, P1019, DOI 10.1016/j.jval.2011.05.045-
hcfmusp.relation.referenceDecimoni TC, 2014, VALUE HEALTH, V17, pA438, DOI 10.1016/j.jval.2014.08.1138-
hcfmusp.relation.referenceDrummond M, 2005, METHODS EC EVALUATIO-
hcfmusp.relation.referenceDurham DP, 2013, VACCINE, V31, P3957, DOI 10.1016/j.vaccine.2013.06.036-
hcfmusp.relation.referenceNovaes HMD, 2015, VACCINE, V33, pA135, DOI 10.1016/j.vaccine.2014.12.031-
hcfmusp.relation.referenceFerraz M L, 1995, Rev Soc Bras Med Trop, V28, P393-
hcfmusp.relation.referenceFleurence RL, 2010, PHARMACOECONOMICS, V28, P295, DOI 10.2165/11530530-000000000-00000-
hcfmusp.relation.referenceFonseca Allex Jardim da, 2013, Rev Assoc Med Bras (1992), V59, P442, DOI 10.1016/j.ramb.2013.03.004-
hcfmusp.relation.referenceGarcia-Altes A, 2013, VACCINE, V31, P1656, DOI 10.1016/j.vaccine.2013.01.029-
hcfmusp.relation.referenceHartmann M, 2003, BRIT J CANCER, V89, P1405, DOI 10.1038/sj.bjc.6601308-
hcfmusp.relation.referenceHusereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002-
hcfmusp.relation.referenceIsaacman DJ, 2008, CLIN THER, V30, P341, DOI 10.1016/j.clinthera.2008.02.003-
hcfmusp.relation.referenceJang S, 2011, AM J CLIN ONCOL-CANC, V34, P524, DOI 10.1097/COC.0b013e3181f4799b-
hcfmusp.relation.referenceJang S, 2010, BREAST CANCER RES TR, V121, P273, DOI 10.1007/s10549-010-0870-7-
hcfmusp.relation.referenceJauregui B, 2015, VACCINE, V33, pA28, DOI 10.1016/j.vaccine.2014.10.090-
hcfmusp.relation.referenceJauregui B, 2015, VACCINE, V33, pA21, DOI 10.1016/j.vaccine.2014.12.080-
hcfmusp.relation.referenceJit M, 2016, APPL HEALTH ECON HEA, V14, P245, DOI 10.1007/s40258-016-0224-7-
hcfmusp.relation.referenceKawai K, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-250-
hcfmusp.relation.referenceMarseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206-
hcfmusp.relation.referenceMassad E, 2009, EPIDEMIOL INFECT, V137, P241, DOI 10.1017/S0950268808000873-
hcfmusp.relation.referenceDiretrizes Metodologicas, 2014, SECR CIENC SECR CIEN-
hcfmusp.relation.referenceNeumann PJ, 2000, HEALTH AFFAIR, V19, P92, DOI 10.1377/hlthaff.19.2.92-
hcfmusp.relation.referenceNewall AT, 2014, PHARMACOECONOMICS, V32, P525, DOI 10.1007/s40273-014-0162-x-
hcfmusp.relation.referenceOhno-Machado L, 2000, J AM MED INFORM ASSN, P625-
hcfmusp.relation.referencePan XF, 2015, VACCINE, V33, P6164, DOI 10.1016/j.vaccine.2015.09.081-
hcfmusp.relation.referencePereira SM, 2012, LANCET INFECT DIS, V12, P300, DOI 10.1016/S1473-3099(11)70285-7-
hcfmusp.relation.referencePeura PK, 2012, MED DECIS MAKING, V32, P237, DOI 10.1177/0272989X11403834-
hcfmusp.relation.referencePostma MJ, 2013, HUM VACC IMMUNOTHER, V9, P1139, DOI 10.4161/hv.23447-
hcfmusp.relation.referenceSantos AMN, 2004, J HOSP INFECT, V56, P228, DOI 10.1016/j.jhin.2003.12.007-
hcfmusp.relation.referenceSartori AMC, 2012, VACCINE, V30, P7489, DOI 10.1016/j.vaccine.2012.10.056-
hcfmusp.relation.referenceSnedecor SJ, 2009, VACCINE, V27, P4694, DOI 10.1016/j.vaccine.2009.05.062-
hcfmusp.relation.referenceSouza CPR, 2009, J BRAS EC SAUDE, V1, P11-
hcfmusp.relation.referenceSouza CPR, 2009, J BRAS EC SAUDE, V1, P103-
hcfmusp.relation.referenceNeto JT, 2011, HUM VACCINES, V7, P1037, DOI 10.4161/hv.7.10.15987-
hcfmusp.relation.referenceToscano CM, 2013, VACCINE, V31, pC12, DOI 10.1016/j.vaccine.2013.05.033-
hcfmusp.relation.referenceTrotter C L, 2002, Commun Dis Public Health, V5, P220-
hcfmusp.relation.referenceUltsch B, 2016, PHARMACOECONOMICS, V34, P227, DOI 10.1007/s40273-015-0335-2-
hcfmusp.relation.referenceUngar WJ, 2011, PHARMACOECONOMICS, V29, P641, DOI 10.2165/11591570-000000000-00000-
hcfmusp.relation.referenceValachis A, 2012, J CLIN ONCOL, V30, P1316, DOI 10.1200/JCO.2011.38.6078-
hcfmusp.relation.referenceValentim J, 2008, VACCINE, V26, P6281, DOI 10.1016/j.vaccine.2008.07.021-
hcfmusp.relation.referenceVanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087-
hcfmusp.relation.referenceVespa G, 2009, REV PANAM SALUD PUBL, V26, P518, DOI 10.1590/S1020-49892009001200007-
hcfmusp.relation.referenceWalker DG, 2010, VACCINE, V28, P2356, DOI 10.1016/j.vaccine.2009.06.035-
hcfmusp.relation.referenceComission on Macroeconomics and Health Macroeconomics and Health: investing in health for economic development, 2001, REP COM MACR HLTH-
hcfmusp.relation.referenceWorld Health Organization, 2014, PRINC CONS ADD VACC, P140-
dc.description.indexMEDLINE-
dc.identifier.eissn2164-554X-
hcfmusp.citation.scopus7-
hcfmusp.scopus.lastupdate2022-06-17-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MIP
Departamento de Moléstias Infecciosas e Parasitárias - FM/MIP

Artigos e Materiais de Revistas Científicas - FM/MPR
Departamento de Medicina Preventiva - FM/MPR

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/38
LIM/38 - Laboratório de Epidemiologia e Imunobiologia

Artigos e Materiais de Revistas Científicas - LIM/39
LIM/39 - Laboratório de Processamento de Dados Biomédicos

Artigos e Materiais de Revistas Científicas - LIM/48
LIM/48 - Laboratório de Imunologia


Files in This Item:
File Description SizeFormat 
art_SARTORI_A_systematic_review_of_health_economic_evaluations_of_2017.PDF
  Restricted Access
publishedVersion (English)588.81 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.